QBioMed Inc (OTCMKTS:QBIO) announced Monday that the ophthalmologist Dr Rajendra Apte has joined its advisory board.
A distinguished professor of ophthalmology and visual sciences at Washington University in St Louis, Apte is now in charge of a study to investigate the correlation of levels of the bio-marker GDF-15 with the severity and progression of glaucoma.
Read: QBioMed extends clinical trial agreement to study glaucoma drugs with Washington University
In a statement, Q BioMed’s CEO Denis Corin, said Apte’s expertise in ophthalmology will help the company’s efforts to advance the development of MAN-01, a small molecule eye-drop for the treatment of primary open angle glaucoma, and its potential companion diagnostic, GDF-15, a biomarker used to detect the severity of glaucoma.
“We are honored to have Dr Apte join our distinguished team of scientific advisors,” Corin said.
Apte’s other areas of specialty include age-related macular degeneration, diabetic retinopathy, vascular diseases, retinal surgery and retinal neurodegeneration.